Literature DB >> 18385970

[Treatment and care strategies for Alzheimer's disease and related dementias].

H Förstl1.   

Abstract

The majority of elderly demented patients suffers from mixed dementia, with Alzheimer's-type brain changes being the leading cause of cognitive impairment. Cholinesterase inhibitors and memantin improve cognitive performance in dementia, with a symptomatic parallel shift of 8 to 12 months. Disturbances of perception and behaviour can be prohibited or mitigated by antidementia drugs and improved with antidepressants, neuroleptics, and other substances. The somatic and cerebral comorbidity of demented patients offers further options for improving sensory input, cerebral availability of oxygen and glucose, and even secondary prevention. Technical support systems for demented patients which are already available remain largely underused. Psychosocial support is mandatory, even though the advantages of specific interventions have not been demonstrated with scientific rigour.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18385970     DOI: 10.1007/s00115-008-2436-z

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  26 in total

1.  Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: longitudinal cohort study.

Authors:  Marie L Ancelin; Sylvaine Artero; Florence Portet; Anne-Marie Dupuy; Jacques Touchon; Karen Ritchie
Journal:  BMJ       Date:  2006-02-01

2.  Reducing the risk of dementia: efficacy of long-term treatment of hypertension.

Authors:  Rita Peila; Lon R White; Kamal Masaki; Helen Petrovitch; Lenore J Launer
Journal:  Stroke       Date:  2006-04-06       Impact factor: 7.914

Review 3.  Cerebrovascular disease in the elderly: lipoprotein metabolism and cognitive decline.

Authors:  Francesco Panza; Vincenzo Solfrizzi; Anna M Colacicco; Alessia D'Introno; Cristiano Capurso; Rossella Palasciano; Orlando Todarello; Sabrina Capurso; Vincenza Pellicani; Antonio Capurso
Journal:  Aging Clin Exp Res       Date:  2006-04       Impact factor: 3.636

4.  Improving caregiver well-being delays nursing home placement of patients with Alzheimer disease.

Authors:  Mary S Mittelman; William E Haley; Olivio J Clay; David L Roth
Journal:  Neurology       Date:  2006-11-14       Impact factor: 9.910

5.  [Misdemeanor in frontotemporal dementia].

Authors:  J Diehl; J Ernst; S Krapp; H Förstl; N Nedopil; A Kurz
Journal:  Fortschr Neurol Psychiatr       Date:  2006-04       Impact factor: 0.752

6.  [Alzheimer's disease: knowledge and attitudes in a representative survey].

Authors:  Susanne Schwalen; Hans Förstl
Journal:  Neuropsychiatr       Date:  2008

Review 7.  [Mild cognitive impairment with predictors of rapid decline].

Authors:  H Förstl; H Bickel; L Frölich; H J Gertz; A Kurz; J Marksteiner; A U Monsch; J Pantel; R Schmidt; P Schönknecht
Journal:  Dtsch Med Wochenschr       Date:  2008-02       Impact factor: 0.628

8.  Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.

Authors:  Pierre N Tariot; Martin R Farlow; George T Grossberg; Stephen M Graham; Scott McDonald; Ivan Gergel
Journal:  JAMA       Date:  2004-01-21       Impact factor: 56.272

9.  Galantamine treatment of vascular dementia: a randomized trial.

Authors:  A P Auchus; H R Brashear; S Salloway; A D Korczyn; P P De Deyn; C Gassmann-Mayer
Journal:  Neurology       Date:  2007-07-31       Impact factor: 9.910

10.  [The current diagnostic approach for chronic progressive dementia].

Authors:  C Bartels; C W Wallesch
Journal:  Nervenarzt       Date:  2007-05       Impact factor: 1.297

View more
  2 in total

1.  [Antidementia drugs--response or non-response?].

Authors:  H Förstl
Journal:  Internist (Berl)       Date:  2008-03       Impact factor: 0.743

Review 2.  [Neuro-enhancement. Brain doping].

Authors:  H Förstl
Journal:  Nervenarzt       Date:  2009-07       Impact factor: 1.214

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.